Holen Sie sich die Stockscreener-App
2.325
1.05%
-0.015
Schlusskurs vom Vortag:
$2.34
Offen:
$2.35
24-Stunden-Volumen:
126.76K
Relative Volume:
0.24
Marktkapitalisierung:
$167.93M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-113.28M
KGV:
-1.2529
EPS:
-1.8557
Netto-Cashflow:
$-105.55M
1W Leistung:
+5.73%
1M Leistung:
+1.56%
6M Leistung:
+10.26%
1J Leistung:
+103.11%
1-Tages-Spanne:
$2.30
$2.42
1-Wochen-Bereich:
$2.19
$2.485
52-Wochen-Spanne:
$1.10
$3.60
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Firmenname
Acumen Pharmaceuticals Inc
Sektor
Branche
Telefon
617-344-4190
Adresse
1210-1220 WASHINGTON STREET, NEWTON
Compare ABOS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
2.325 | 169.01M | 0 | -113.28M | -105.55M | -1.8557 |
VRTX
Vertex Pharmaceuticals Inc
|
449.32 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
613.56 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.10 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
279.06 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.83 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-07-26 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-07-20 | Fortgesetzt | BofA Securities | Buy |
| 2023-05-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-07-15 | Eingeleitet | BTIG Research | Buy |
| 2022-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-07-26 | Eingeleitet | BofA Securities | Neutral |
| 2021-07-26 | Eingeleitet | Credit Suisse | Outperform |
| 2021-07-26 | Eingeleitet | Stifel | Buy |
| 2021-07-26 | Eingeleitet | UBS | Buy |
Alle ansehen
Acumen Pharmaceuticals Inc Aktie (ABOS) Neueste Nachrichten
Acumen Pharmaceuticals Nominates Two Development Candidates in Enhanced Brain Delivery Program for Alzheimer's Disease Treatment - Quiver Quantitative
Acumen (NASDAQ: ABOS) advances two EBD Alzheimer’s drug candidates - Stock Titan
Two new antibody designs aim for higher brain delivery in Alzheimer’s - Stock Titan
[144] Acumen Pharmaceuticals, Inc. SEC Filing - Stock Titan
Bank of America Securities Keeps Their Buy Rating on Acumen Pharmaceuticals (ABOS) - The Globe and Mail
Acumen Pharmaceuticals Q1 earnings call highlights - MSN
Acumen Pharmaceuticals director sells $14,272 in company stock By Investing.com - Investing.com Nigeria
Acumen Pharmaceuticals director sells $14,272 in company stock - Investing.com
Insider Sell: Nathan Fountain Sells 6,400 Shares of Acumen Pharm - GuruFocus
Acumen Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Fountain Nathan B - Moomoo
Director Nathan Fountain sells 6,400 Acumen (ABOS) shares at ~$2.23 - Stock Titan
ABOS Q1 2026 Earnings: Narrower-than-Expected Loss as Phase 2 Readout ApproachesDownward Estimate Revision - newsline.com
Acumen (NASDAQ: ABOS) director equity grant tied to RA Capital funds - Stock Titan
Acumen Pharmaceuticals (NASDAQ: ABOS) director receives RSU and option grants - Stock Titan
Acumen (NASDAQ: ABOS) director granted RSUs and options vesting by 2027 - Stock Titan
Acumen Pharmaceuticals (ABOS) director receives new RSU and option awards - Stock Titan
Acumen Pharmaceuticals (ABOS) grants RSUs and stock options to director - Stock Titan
Acumen Pharmaceuticals (ABOS) director receives RSU and option grants - Stock Titan
Acumen Pharmaceuticals (NASDAQ: ABOS) director awarded RSUs and options - Stock Titan
Acumen Pharmaceuticals (ABOS) director awarded RSUs and options for RA Capital - Stock Titan
Acumen Stockholders Approve Directors and Equity Incentive Plan - TipRanks
Acumen Pharmaceuticals (NASDAQ: ABOS) investors approve equity plan and auditor - Stock Titan
Acumen Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $7.4, Implies 212% Upside - TradingView
Acumen Pharmaceuticals, Inc. pushes research for brain health as dementia numbers climb - Traders Union
Acumen Pharmaceuticals (ABOS) Holds Near Key Support After Slight Upside MoveAdvance Decline Volume - newsline.com
Is Acumen Pharmaceuticals (ABOS) stock outpacing its medical peers this year? - MSN
Acumen Pharmaceuticals Bets Big on Alzheimer’s Trials - TipRanks
ABOS Technical Analysis | Trend, Signals & Chart Patterns | ACUMEN PHARMACEUTICALS INC (NASDAQ:ABOS) - ChartMill
ABOS - Finviz
Why ABOS Stock Barely Moved While Acumen’s Alzheimer’s Data Clock Keeps Ticking - Bez Kabli
Acumen Pharmaceuticals (ABOS) Gains Nearly 5% as Stock Tests Resistance at $2.67Break of Structure - The Legal Advocate
Acumen Pharmaceuticals (ABOS) Slides 3.59%, Testing Near-Term SupportJelly Roll Trade - The Legal Advocate
B of A Securities Maintains Acumen Pharmaceuticals (ABOS) Buy Recommendation - MSN
Acumen Pharmaceuticals (ABOS) Edges Higher Amid Low Volume, Tests Key Resistance LevelsStraddle Setup - The Legal Advocate
Acumen Pharmaceuticals (ABOS) Holds Ground Near Resistance: Can Biotech Momentum Continue?High Beta Stocks - The Legal Advocate
Acumen Pharmaceuticals (ABOS) Price Target Decreased by 20.59% to 6.88 - MSN
Acumen Pharmaceuticals Q1 2026 Earnings: Narrowed Loss Surprises as Alzheimer’s Pipeline AdvancesCapex Guidance - Newser
Acumen Pharmaceuticals (ABOS) Gains Momentum: Support Holds at $2.37, Resistance at $2.61 in FocusValue Area High - Newser
Acumen’s Late-2026 Sabirnetug Readout Is A Viable Bet (NASDAQ:ABOS) - Seeking Alpha
Bank of America Securities Remains a Buy on Acumen Pharmaceuticals (ABOS) - The Globe and Mail
BofA Securities Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Earnings call transcript: Acumen Pharmaceuticals beats Q1 2026 EPS forecast - Investing.com
Acumen Pharmaceuticals (ABOS) loses 33.6% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Acumen Pharmaceuticals Warns Investors: Unchanged 10-K Risk Factors Still Weigh on Valuation and Share Price - TipRanks
Acumen Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript - Sahm
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2026 Earnings Call Transcript - Insider Monkey
Acumen Pharmaceuticals 1Q 2026: Net loss $(20.7)M, EPS $(0.33) — 10-Q Summary - TradingView
[10-Q] Acumen Pharmaceuticals, Inc. Quarterly Earnings Report - Stock Titan
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TradingKey - TradingKey
Finanzdaten der Acumen Pharmaceuticals Inc-Aktie (ABOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Acumen Pharmaceuticals Inc-Aktie (ABOS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Fountain Nathan B | Director |
Jun 09 '26 |
Sale |
2.23 |
6,400 |
14,273 |
48,150 |
2.40%
0.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):